Trial | NCT00563927  Report issue

Title

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    340
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
Study Started
Mar 31
1999
Study Completion
Oct 31
2009
Anticipated
Last Update
Jul 07
2010
Estimate

Procedure Conventional RT

Drug Cisplatin

Drug 5-fluorouracil

Criteria 

Inclusion Criteria:

Undifferentiated or non-keratinizing carcinoma
Tumor staged as N2-3
No evidence of distant metastasis M0
Performance status:0-2
Marrow: WBC >= 4 and platelet >= 100
Renal: creatinine clearance >= 60
Informed consent

Exclusion Criteria:

WHO type I squamous cell carcinoma or adenocarcinoma
Age >= 70
Palliative intent or tumor extent mandating AP opposing facio-cervical fields
Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years
Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume
Previous chemotherapy
Patient is pregnant or lactating
No Results Posted